Investors are beginning to doubt Regeneron Pharmaceuticals' research prowess, an analyst said Tuesday, noting Regeneron stock has slid 33% since March. Year-to-date, the stock has lost 21%.
Investors are beginning to doubt Regeneron Pharmaceuticals' research prowess, an analyst said Tuesday, noting Regeneron stock has slid 33% since March. Year-to-date, the stock has lost 21%.
blaineonline.finance.blog 